Drug Profile

STP 779

Alternative Names: STP-779

Latest Information Update: 25 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sirnaomics
Class Antineoplastics; Small interfering RNA
Mechanism of Action RNA interference; Sulfatase modulators; Transforming growth factor beta1 expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Cholangiocarcinoma; Liver cancer; Lung cancer; Pancreatic cancer

25 May 2022 Sirnaomics plans to file IND application to initiate clinical trial of STP 779 for Cholangiocarcinoma, in 2023
20 May 2022 Preclinical trials in Cholangiocarcinoma in USA (IV), prior to May 2022
01 Oct 2021 Preclinical trials in Liver cancer in USA (IV) (Sirnaomics pipeline, October 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com